The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials
Open accessAbstract
RATIONALE: FVC has emerged as a standard primary endpoint in clinical trials evaluating novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently been proposed that all-cause mortality or a composite comprised of all-cause mortality and all-cause nonelective hospitalization be adopted as the standard primary endpoint for IPF clinical trials. OBJECTIVES: To conduct a comprehensive evaluation of mortality in three phase 3 clinical trials and evaluate the feasibility of mortality trials in patients with IPF. METHODS: The study population included 622 patients randomized to placebo in the CAPACITY studies evaluating pirfenidone (n = 347) or the INSPIRE study evaluating interferon-γ1b (n = 275). The Kaplan-Meier estimate of 2-year survival was fit to the exponential distribution and used to calculate sample size requirements for a mortality study with 90% power to detect a 25% reduction in all-cause mortality with a two-sided α of 0.05. Modeling analyses were used to assess the effects of selected variables on sample size and study design. MEASUREMENTS AND MAIN RESULTS: A total of 73 deaths occurred during the period of observation (mean duration of follow-up, 80.1 wk). The all-cause mortality rate was 6.6% at 1 year and 13.7% at 2 years. Based on the observed 2-year mortality rate, a total of 508 events would be required to detect a significant treatment benefit in a two-arm trial with 90% power to detect a 25% reduction in all-cause mortality. The estimated sample size for a trial enrolled over 3 years with a maximum follow-up period of 5 years is 2,582 patients. CONCLUSIONS: The all-cause mortality rate is relatively low in patients with IPF with mild to moderate impairment in lung function. Accordingly, the necessary size, duration, and cost of all-cause mortality trials in this population are substantial and likely prohibitive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citationMills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338
Cited by
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citationIncidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old
Raghu, G., Chen, S.-Y., Hou, Q., Yeh, W.-S., & Collard, H. R. (2016) · European Respiratory Journal · doi:10.1183/13993003.01653-2015 · Cited by 338
Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., Kardatzke, D. R., Daigl, M., Kirchgaessler, K.-U., Lancaster, L. H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30326-5 · Cited by 335
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017) · European Respiratory Review · doi:10.1183/16000617.0057-2017 · Cited by 295
Self-citationEvaluating disease severity in idiopathic pulmonary fibrosis
Robbie, H., Daccord, C., Chua, F., & Devaraj, A. (2017) · European Respiratory Review · doi:10.1183/16000617.0051-2017 · Cited by 93
Metadata
- Authors
- King, T. E., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Leff, J. A., Nathan, S. D., Sahn, S. A., Valeyre, D., & Noble, P. W.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-01
- Volume
- 189
- Issue
- 7
- Pages
- 825-831
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2013155459
- Cited by
- 158
- References
- 2
- FWCI
- 16.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials. https://app.cochat.ai/papers/10.1164/rccm.201311-1951oc
- The paper
- King, T. E., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Leff, J. A., Nathan, S. D., Sahn, S. A., Valeyre, D., & Noble, P. W. (2014). All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201311-1951oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.